Table 1.
Univariate analysis of characteristics associated with a progression during induction chemotherapy.
| Characteristics | OR for progression | [95% CI], p value | |
|---|---|---|---|
| Gender | Female vs male | 1.28 | [0.79–2.07], p = 0.31 |
| Age | ≤65 vs >65 | 1.16 | [0.73–1.86], p = 0.52 |
| WHO performance status |
1 vs 0 2 vs 0 |
1.59 3.79 |
[0.95–2.65], p = 0.43 [1.78–8.09], p = 0.002 |
| Primary tumour resected | No vs yes | 1.26 | [0.79–2.02], p = 0.33 |
| Number of metastatic sites | >1 vs 1 | 1.16 | [0.71–1.88], p = 0.55 |
| Primary location | Right colon vs left colon or rectum | 0.87 | [0.62–1.31], p = 0.41 |
| Baseline leukocytes | >10 × 109/L vs ≤10 × 109/L | 1.91 | [1.16–3.15], p = 0.01 |
| Baseline platelet | ≥400 × 109/L vs <400 × 109/L | 1.68 | [0.92–3.08], p = 0.09 |
| Baseline alkaline phosphatase | >300 vs ≤300 U/L | 1.39 | [0.79–2.44], p = 0.25 |
| Baseline CEA | >ULN vs normal | 2.46 | [0.86–7.09], p = 0.10 |
| Two months CEA vs baseline CEA | Stable or increase vs decrease >50% | 3.00 | [1.44–6.23], p = 0.01 |
| Tumour KRAS | Mutated vs wild type | 1.12 | [0.65–1.92], p = 0.70 |
| Tumour BRAF | Mutated vs wild type | 1.30 | [0.42–4.04], p = 0.65 |
CEA carcinoembryonic antigen, ULN upper limit of normal.